

Senior Management

Franz Hefti

President & CEO

Hampus Hillerstrom

EVP & CFO

Richard A. Fisher, PhD

CSO

Michael Grundman, MD, PhD

Clinical Development Leader

Roxanne Bales

VP Regulatory & Compliance

Jason L. Wright, PhD

VP Manufacturing

Scientific Advisory Board

Paul Aisen, MD

UCSD

David Hafler, MD

Yale

David Holtzman, MD

Washington University

Brad Hyman, MD, PhD

Harvard

Kenneth Marek, MD

Molecular Neuroimaging

Greg Petsko, PhD

Brandeis

Beka Solomon, PhD

Tel Aviv University

Board of Directors

Daniel Lynch, MBA (Exec. Chair)

Partner, Third Rock Ventures

Kenneth A. Buckfire

President, Miller Buckfire & Co.

John Dee, MS, MBA

CEO, Novion Pharmaceuticals

Paul Goldenheim, MD

ex-President of Transform

Franz Hefti, PhD

Proclara Biosciences

Nick Leschly, MBA

CEO, Bluebird Bio

Hans Schoepflin

Schoepflin Investment Company

Company overview

- Founded in 2007, 17 employees, based in Cambridge, MA
- Novel, **breakthrough discovery** targeting multiple toxic **misfolded proteins** with broad applications in aging disorders
- Diseases of aging represent the **world's largest unmet medical need**
- **NPT088: highly differentiated drug candidate** currently in clinical trials in Alzheimer's disease
- **Strong drug development and management expertise**
- **Comprehensive IP Portfolio** for novel mechanism, compositions, and therapeutic uses
- **Over \$110M in financing raised** to date including a Part the Cloud grant from the Alzheimer's Association; also received two Michael J. Fox grants awards for Parkinson's research
- Collaborations with leading institutions: NIH, MGH/Harvard, UCSD, Washington University, Rush University, NYU.
- Part of GE HealthCare Consortium for access to the tau imaging agent [¹⁸F] THK-5351.

Unique Platform and Opportunity in Neurodegenerative Diseases

- All misfolded protein aggregates share a targetable "amyloid fold"
- **Proclara simultaneously targets multiple disease-causing misfolded proteins, avoiding single-target limitations of most current approaches**
- Proclara's General Amyloid Interaction Motif (GAIM)-based molecules bind to and remodel misfolded protein assemblies and facilitate their clearance.
- Another advantage of Proclara's GAIM-based molecules is that they target plaque specifically and do not interact with monomers.
- Advances in PET imaging for amyloid beta and tau allow early Proof-of-Activity to unlock broader clinical potential.

Pipeline

- **NPT088:** lead candidate Ig fusion protein combining GAIM motif with a portion of human antibody; simultaneously targets amyloid-beta, tau and alpha synuclein (initial indication: Alzheimer's disease);
 - IND filed end 2015; 6-month dosing Phase 1b study with PET imaging readout for amyloid-beta and tau and cognitive assessment on going with data expected April 2018.
- **NPT189:** back-up candidate Ig fusion protein, targeting systemic amyloidosis diseases, in early preclinical development.
- **GAIM platform:** discovery and development of next generation candidates with improved properties.